Chinese Appetite For Medtech Could Shrink In Face Of Uncertainty
Executive Summary
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
You may also be interested in...
Intuitive Surgical, Fosun Pair Up For Lung Cancer JV
Intuitive Surgical is setting up a China-based joint venture with its distribution partner Fosun Pharma that will develop robotic-assisted, catheter-based devices for diagnosing and treating lung cancer.
China’s Big And Small Next-Gen Sequencing Players Ride The Precision Medicine Wave
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
China's new biosimilars guideline: more flexibility, but stricter in parts
The China Food and Drug Administration has released the final version of its biosimilars guideline1.